{"entity":{"id":"nct06087653","kind":"trial","name":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)","aka":[],"tldr":"A phase 1/2 trial of Lenalidomide, Dexamethasone in multiple myeloma, run by Starton Therapeutics, Inc, now recruiting.","summary":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) is a phase 1/2 interventional study registered as NCT06087653 by Starton Therapeutics, Inc, with 24 participants planned, started 2023-10-02 and due to reach its primary completion in 2027-05-31. Interventions recorded: Lenalidomide, Lenalidomide 25 MG Oral Capsule. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06087653","url":"https://clinicaltrials.gov/study/NCT06087653"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["lenalidomide","dexamethasone"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06087653","phase":"1/2","setting":"A Protocol to Assess the Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Administration of Low-dose Lenalidomide (STAR-LLD) for the Treatment of Multiple Myeloma (MM)","sponsor":"Starton Therapeutics, Inc","enrolled":24,"outcomes":[]},"route":"/trials/nct06087653/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"}]}}